Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;196(2):433-437.
doi: 10.1111/bjh.17692. Epub 2021 Dec 3.

A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients

HaemSTAR Collaborators
Collaborators

A single 1 g/kg dose of intravenous immunoglobulin is a safe and effective treatment for immune thrombocytopenia; results of the first HaemSTAR 'Flash-Mob' retrospective study incorporating 961 patients

HaemSTAR Collaborators. Br J Haematol. 2022 Jan.
No abstract available

PubMed Disclaimer

References

    1. StasiR, NewlandAC. ITP: a historical perspective. Br J Haematol. 2011;153:437-50.
    1. GodeauB, ChevretS, VaretB, LefrèreF, ZiniJM, BassompierreF, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359:23-9.
    1. MisbahSA, MurphyMF, PavordS, HillQ, CosterR, MatthewsM, et al. Outcome of national oversight of intravenous immunoglobulin prescribing in immune thrombocytopenia. J Clin Pathol. 2020;74:678-9.
    1. DebesA, BauerM, KremerS. Tolerability and safety of the intravenous immunoglobulin Octagam®: a 10-year prospective observational study. Pharmacoepidem Drug Safe. 2007;16:1038-47.
    1. GuoY, TianX, WangX, XiaoZ. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:15-13.

Publication types

MeSH terms

Substances

LinkOut - more resources